Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses challenges facing genetic testing for patients with prostate cancer.

According to Kane, the technology often outstrips the ethics and the clinical precision data. We have multiple ways to obtain various genetic data, but physicians are still unsure of the next steps following that information.

It is still quite early in the genetic testing space, so more studies are required to develop new data, states Kane.

Videos

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses challenges facing genetic testing for patients with prostate cancer.


Dr. Kane on Challenges Facing Genetic Testing in Prostate Cancer

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses the impact of genetic testing on patients with prostate cancer.  

Genetic testing for patients with prostate cancer can have a broad impact on who needs to be screened and who can benefit from screening. Many times, when patients come in for screening, they don’t know their family history, explains Kane.  

The genomic risk that might be inherited in your germline could influence the type of prostate cancer a patient could have and how sensitive that prostate cancer is to different types of treatment, states Kane. 

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses the impact of genetic testing on patients with prostate cancer. 


Dr. Kane on Genetic Testing for Prostate Cancer

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses high-penetrance genetic syndromes in patients with prostate cancer.

Many urologists don’t think of prostate cancer as one of the high-penetrance genetic syndromes, especially when compared to kidney cancer, Kane explains.

About 5% to 8% of patients with kidney cancer have a genetic autosomal dominant high-penetrance syndrome. Understanding the recommendation for testing for these syndromes will influence how to tackle the emerging evidence of the genomic and genetic prostate cancer risk, explains Kane.

Christopher J. Kane, MD

Articles

Dr. Kane on Challenges Facing Genetic Testing in Prostate Cancer

Dr. Kane on Genetic Testing for Prostate Cancer

Dr. Kane on High-Penetrance Genetic Syndromes in Prostate Cancer